Clinical trials: Locally Advanced Oropharyngeal Carcinoma
Head and Neck Cancer
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00281840
- Testing
- bevacizumab, docetaxel, conventional surgery
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Head and Neck Cancer, Squamous Cell Carcinoma
Pembrolizumab in Combination With CRT for LA-SCCHN
This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemoradiotherapy (CRT) in patients with stage III-IVB squamous cell carcinoma of the…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT02586207
- Testing
- pembrolizumab (MK-3475), Cisplatin, Radiation
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanford Health
Oral Mucositis
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers.
- Trial name
- PREVLAR (NCT03515538)
- Testing
- RRx-001, Cisplatin for injection, Radiation Therapy
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- EpicentRx, Inc.
Head and Neck Cancer
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00721513
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer, Mucositis
Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer
RATIONALE: Growth factors, such as palifermin, may lessen the severity of mucositis, or mouth sores, in patients receiving radiation therapy and chemotherapy for head and neck cancer.
- Conditions
- Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
- Trial name
- NCT00360971
- Testing
- palifermin, cisplatin, neck dissection
- Where
- 48 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Radiation Therapy Oncology Group
Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
In this research study, the investigators are studying whether a reduced dose of radiation when given with standard doses of chemotherapy can reduce side effects without compromising control of the cancer.
- Trial name
- NCT01221753
- Testing
- docetaxel, cisplatin, 5-FU
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Cancer
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00720304
- Testing
- docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Case Comprehensive Cancer Center
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Erlotinib hydrochloride may also make tumor cells more sensitive to radiation therapy.
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT01192815
- Testing
- erlotinib hydrochloride, intensity-modulated radiation therapy, pharmacogenomic studies
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Case Comprehensive Cancer Center
Head and Neck Cancer
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352105
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- David Adelstein
Head and Neck Cancer
Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00851877
- Testing
- Cetuximab, Cisplatin, Nab-Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Texas Southwestern Medical Center
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer.
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT01898494
- Testing
- Transoral surgery, intensity-modulated radiation therapy, cisplatin
- Where
- 58 sites in United States
- Volunteers
- 519 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Head and Neck Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352118
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
This phase II trial investigates how well sodium thiosulfate works in preventing ototoxicity (hearing loss/damage) in patients with squamous cell cancer of the head and neck that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT04541355
- Testing
- Cisplatin, Hearing Handicap Inventory for Adults - Screening, Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Hyunseok Kang, MD
Head and Neck Cancer
Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00503997
- Testing
- oxaliplatin, pemetrexed disodium
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
This phase I trial studies the side effects and best dose of berzosertib (M6620) when given together with cisplatin and radiation therapy in treating patients with head and neck squamous cell carcinoma that has spread from where…
- Conditions
- Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT02567422
- Testing
- Berzosertib, Cisplatin, Computed Tomography
- Where
- 19 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Radiation Induced Oral Mucositis
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in…
- Trial name
- NCT02508389
- Testing
- Low Dose GC4419: 30mg/day, High Dose GC4419: 90mg/day, Intensity-Modulated Radiation Therapy
- Where
- 64 sites in United States, Canada and 1 more
- Volunteers
- 223 people
- Sponsor
- Galera Therapeutics, Inc.
Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma
- Trial name
- NCT02113878
- Testing
- BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Cancer
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses over a shorter period of time, may…
- Trial name
- NCT00956007
- Testing
- cetuximab, intensity-modulated radiation therapy
- Where
- 264 sites in United States, Canada and 2 more
- Volunteers
- 702 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544414
- Testing
- cisplatin, docetaxel, fluorouracil
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Chemotherapeutic Agent Toxicity, Mucositis
Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01682031
- Testing
- selenomethionine, cisplatin, radiation therapy
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute